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 distinct CSF biomarker patterns in FTD and PPA as major 
 subgroups of frontotemporal lobar degeneration. The diag-
nostic and pathophysiological implications of our results 
warrant further studies on larger and neuropathologically 
diagnosed patient populations. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Over the past 10 years, characteristic cerebrospinal 
fluid (CSF) biomarker patterns have been established to 
support the clinical diagnosis of Alzheimer’s dementia 
(AD). The main protagonists are amyloid-  (A  ) 1–42 , tau 
and its phosphorylated forms (e.g. p-tau 181). In contrast, 
the literature about specific biomarkers for other com-
mon neurodegenerative disorders, such as frontotempo-
ral lobar degeneration (FTLD), is sparse. FTLD is defined 
as a generic term to summarize heterogeneous clinical 
phenotypes that may appear sporadically or be caused by 
various genetic mutations. There is also great heterogene-
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 Abstract 
 Background/Aims: We determined cerebrospinal fluid (CSF) 
concentrations of amyloid-  (A  ) 1–38 , A  1–40 , A  1–42 , total tau 
and phospho-tau (p-tau) in order to study their differential 
expression in frontotemporal dementia (FTD, n = 25) and 
 primary progressive aphasia (PPA, n = 12) as compared to 
Alzheimer’s dementia (AD, n = 25) and nondemented con-
trols (n = 20).  Methods: Commercially available ELISA and 
electrochemiluminescence methods were applied.  Results: 
High CSF p-tau and low ratios of A  1–42 /A  1–40 and A  1–42 /
A  1–38 , respectively, were specific for AD. CSF A  1–38 was re-
duced in FTD as compared to each of the other diagnostic 
groups, including PPA. CSF tau and p-tau levels were elevat-
ed in PPA as compared to FTD.  Conclusion: This is the first 
detailed report on biomarker patterns in PPA, indicating 
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ity in neuropathologic findings, but the present study fo-
cuses on the clinical definition of diagnostic groups. 
Three sets of criteria for clinically diagnosing FTLD have 
been published so far. The clinical criteria by Neary et al. 
 [1] are most helpful when focussing on the 3 prototypic 
clinical subtypes of FTLD: frontotemporal dementia 
(FTD), primary progressive aphasia (PPA) and semantic 
dementia. However, clinical diagnosis among these sub-
groups often remains crucial in a definite case. Thus, bio-
markers for applicable diagnostic testing are warranted 
and still deserve intensive investigation. There are previ-
ous reports about the aforementioned AD-specific bio-
markers in FTLD and FTD, revealing rather unspecific 
alterations  [2–4] . Two reports have focussed on A  1–40 in 
FTLD, one of which showed a decrease in comparison to 
controls and AD  [5] . The other did not include a com-
parison group, but reported an inverse correlation of CSF 
A  1–40 with frontal lobe volume in 11 FTD patients  [6] . 
Our group reported decreased A  1–37 and A  1–38 levels as 
part of disease-specific CSF A  peptide patterns in FTLD 
and FTD  [7, 8] , using the A  -SDS-PAGE with Western 
immunoblot (A  -SDS-PAGE/immunoblot). Interesting-
ly, electrochemiluminescence measurements confirmed 
decreased CSF A  1–38 levels in FTD, but with consider-
ably lower test accuracy for diagnosing the disease in a 
single case  [9] . Other biomarker findings for FTD include 
slightly elevated levels of TAR DNA-binding protein 43 
and differences in processing soluble ectodomain of the 
amyloid precursor protein  [10, 11] .
 PPA represents another major subgroup of FTLD, but 
very little is known about its CSF biomarker patterns. 
This prompted us to determine the major A  species in 
CSF 1–40, 1–38 and 1–42 in addition to total tau and p-
tau 181 in patients with FTD (n = 25) and PPA (n = 12), 
as compared to AD (n = 25) and nondemented disease 
controls (NDC, n = 20).
 Patients and Methods 
 Eighty-two CSF samples were referred to our laboratory be-
tween 1999 and 2004 and investigated. CSF concentrations of 
A  1–38 (n = 82), A  1–40 (n = 78), A  1–42 (n = 73), p-tau 181 (n = 78) 
and tau (n = 58) were measured. Aliquots of these samples had 
been studied previously under another objective, focussing on a 
distinct issue of differentially diagnosing dementias  [8] . CSF of 
AD and other dementia and depressive patients came from the 
memory clinic of the University of Göttingen or from wards. Cog-
nitive impairment was assessed at least by Mini-Mental State Ex-
amination (MMSE). More detailed neuropsychological testing in-
cluding clock drawing and the CERAD (Consortium to Establish 
a Registry for Alzheimer’s Disease) test battery was additionally 
carried out on the majority of patients with cognitive complaints 
(46/72). Specifically, 5/10, 10/25, 21/25 and 10/12 patients under-
went neuropsychological testing in the groups of depressive cog-
nitive complainers (DCC), and AD, FTD and PPA patients, re-
spectively. Detailed neuropsychological assessment was hindered 
in 2 patients with FTD and 2 patients with PPA by severe lingual 
or cognitive deficits.
 A psychiatrist, a neurologist and a neuropsychologist rendered 
diagnoses based on a thorough medical history, clinical examina-
tion, neuropsychological assessment, clinical records and best 
clinical judgment. The investigators were blinded to the neuro-
chemical outcome measures. Investigations were carried out with 
the informed consent of patients or their authorized caregivers. 
The study was conducted under the guidelines of the Declaration 
of Helsinki  [12] and approved by the ethics committee of the Uni-
versity of Göttingen.
 Patients 
 Nondemented Disease Controls. The NDC group consisted of 
2 subgroups: (1) patients with peripheral neurological diseases 
(PND) without organic brain affection, and (2) DCC. The 10 pa-
tients in the PND subgroup underwent lumbar puncture to inves-
tigate central nervous affection in case of polyneuropathy (n = 7), 
benign paroxysmal positioning vertigo (n = 1), intervertebral disk 
herniation (n = 1), autosomal dominant hereditary spastic spinal 
palsy (n = 1). The 10 DCC underwent lumbar puncture for differ-
ential diagnosis of cognitive complaints during the course of dis-
ease. The diagnosis of depression was made according to the cri-
teria of the DSM-IV, and cognitive impairment was assessed at 
least by the MMSE. Patients with persistent cognitive decline for 
more than 6 months, an MMSE score below 26 or clear focal at-
rophy in brain imaging (CT or MRI) were excluded.
 Patients with AD. Twenty-five patients fulfilled the DSM-IV 
criteria and NINCDS-ADRDA criteria for clinical diagnosis of 
AD  [13] . Structural (CT or MRI) or functional (single-photon-
emission CT or positron emission tomography) brain imaging 
displayed global cortical atrophy, or temporal, parietotemporal or 
frontotemporal focal atrophy, or marked hypometabolism of 
these regions.
 Patients with FTD and PPA. FTD (n = 25) and PPA (n = 12) 
were diagnosed according to the consensus criteria  [1] . Structural 
(CT or MRI) or functional (single-photon-emission CT or posi-
tron emission tomography) brain imaging revealed frontal or 
frontotemporal focal atrophy or marked hypometabolism in case 
of FTD, and left anterior temporal focal atrophy or marked hypo-
metabolism in case of PPA. 
 Test Methods 
 Preanalytical Treatment of CSF. CSF was drawn by lumbar 
puncture into polypropylene vials and centrifuged (1,000  g , 10 
min, 4  °  C). Aliquots of 200   l were kept at room temperature for 
a maximum of 24 h before storage at –80  °  C for subsequent p-tau, 
A  1–38 and A  1–40 analysis. CSF for A  1–42 and total tau ELISA 
analysis was stored at +4  °  C and analyzed within 2 days.
 ELISA for p-Tau, Total Tau Protein and A  1–42 and A  1–40 . 
ELISA for p-tau at Thr181 was conducted as previously described 
 [14] . Briefly, the HT7 monoclonal antibody (MAb) directed 
against both normal tau and p-tau was used for capturing, and 
biotinylated MAb AT270 for detection. According to published 
standard methods  [15] , the Innotest hTAU Antigen ELISA and 
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Innotest   -Amyloid 1–42 (ELISA Innogenetics, Ghent, Belgium) 
served for quantification of CSF tau and A  1–42 , respectively. For 
the quantification of A  1–40 , the ELISA of The Genetics Company 
was conducted similarly, except that before application to a mi-
crotiter plate, the samples were prediluted 1: 5 with diluting buffer.
 Electrochemiluminescence Detection of A  1–38 . Electrochemi-
luminescence detection of A  1–38 in CSF was performed accord-
ing to the manufacturer’s recommendations (Meso Scale Discov-
ery). In brief, Multi-Spot 4-spot 96-well plates, precoated with 
MAb 6E10, were blocked with solution A. The plate was then in-
cubated with a reference peptide dilution series or 100   l CSF for 
1 h, followed by incubation with C-terminal Sulfo-Tag A  1–38 an-
tibody and finally Read Buffer, for 1 h each. Washing steps with 1 
 ! Tris buffer were performed in between. The emitted light was 
measured at approximately 620 nm.
 Statistical Analysis 
 A  peptides, tau and p-tau were expressed as absolutes (in 
nanograms per milliliter). Patient groups were characterized by 
mean and SD. The Mann-Whitney U test was employed for com-
parisons of diagnostic groups. Correlations were estimated by 
Spearman’s rho. The two-sided level of significance was taken as 
p  ! 0.05. The statistical software package SPSS, version 12.0, 
served for computations.
 Results 
 Test Results 
 The mean age of FTD and PPA patients was signifi-
cantly below that of the AD group (p  ! 5  ! 10 –2 ). Other-
wise, there was no significant difference in age among the 
diagnostic groups. The mean MMSE score did not sig-
nificantly differ between the dementia groups. There was 
no significant difference among PND patients and DCC 
in any of the parameters investigated. For the following 
statistical evaluation, the 2 groups were therefore consid-
ered as one (NDC). The respective CSF concentrations 
underlying the following comparisons are displayed in 
 figures 1–5 .
 Neurochemical Phenotype of AD versus NDC. A  1–42 
























































































 Fig. 1. Means and 95% CI of CSF p-tau concentrations for each 
diagnostic group.  *  p  ! 0.05. 
 Fig. 2. Means and 95% CI of CSF tau concentrations for each di-
agnostic group.  *  p  ! 0.05. 
 Fig. 3. Means and 95% CI of CSF A  1–38 concentrations for each 
diagnostic group.  *  p  ! 0.05. 
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as A  1–40 levels were virtually unchanged between the 2 
groups. A  1–38 tended to be increased in AD, but missed 
the level of significance. Consequently, the ratios of
A  1–42 /A  1–40 (p = 8.0  ! 10 –10 ) and A  1–42 /A  1–38 (p = 
2.0  ! 10 –8 ) showed a decrease in AD. A  1–38 /A  1–40 was 
significantly elevated in AD ( table 1 ). CSF total tau (p = 
2.4  ! 10 –4 ) and p-tau (p = 1.4  ! 10 –6 ) were elevated in 
AD.
 Neurochemical Phenotype of FTD versus NDC. FTD 
patients showed lower levels of A  1–38 (p = 4.1  ! 10 –4 ), 
A  1–42 (p = 3.2  ! 10 –3 ) and A  1–40 (p = 9.7  ! 10 –4 ) than 
NDC. The A  ratios remained virtually unchanged be-
tween FTD and NDC. CSF total tau did not significantly 
differ, whereas p-tau was lowered in FTD (p = 5.3  ! 10 –3 ).
 Neurochemical Phenotype of FTD versus AD. In com-
parison to AD, FTD showed lower levels of A  1–38 (p =
























































 Fig. 4. Means and 95% CI of CSF A  1–40 concentrations for each 
diagnostic group.  *  p  ! 0.05. 
 Fig. 5. Means and 95% CI of CSF A  1–42 concentrations for each 
diagnostic group.  *  p  ! 0.05. 
Table 1.  Total and p-tau, and A peptides 1–38, 1–40 and 1–42 in CSF of diagnostic groups
NDC (n = 20) AD (n = 25) FTD (n = 25) PPA (n = 12)
Age, years 65.0589.4 71.5688.6 58.92810.2 62.33810.1
Sex (m/w), n 11/9 5/20 17/8 10/2
In-/outpatients, n 10/10 10/15 13/12 6/6
MMSE score 28.2781.7 17.0686.2 19.74810.1 17.50812.8
p-tau ELISA 1, ng/ml 0.05580.02 0.11480.04 0.04180.01 0.05880.03
Tau ELISA 1, ng/ml 0.25280.14 0.60180.31 0.25280.25 0.37080.22
A1–381, ng/ml 0.85780.20 0.98480.28 0.62380.20 0.80680.20
A1–402, ng/ml 6.49281.63 6.22581.82 4.60381.60 5.50381.51
A1–422, ng/ml 0.97180.30 0.38480.16 0.70980.20 0.75480.26
A1–38/A1–40, ng/ml 0.13480.02 0.16580.03 0.14380.04 0.15580.06
A1–42/A1–38, ng/ml 1.17780.39 0.37780.16 1.19880.43 1.00980.39
A1–42/A1–40, ng/ml 0.15880.05 0.06480.02 0.15880.07 0.14880.06
1 A peptide concentrations as measured by electrochemiluminescence detection (Meso Scale Discovery).
2 A peptide concentrations as measured by ELISA.
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els of A  1–42 (p = 8.7  ! 10 –7 ). Consequently, the ratios
of A  1–42 /A  1–40 (p = 2.8  ! 10 –7 ) and A  1–42 /A  1–38 (p = 
1.9  ! 10 –8 ) were decreased in AD, while A  1–38 /A  1–40 
was lowered in FTD (p = 2.3  ! 10 –2 ) ( table 1 ). CSF total 
tau (p = 6.3  ! 10 –6 ) and p-tau (p = 4.2  ! 10 –9 ) were 
 elevated in AD.
 Neurochemical Phenotype of PPA versus NDC. PPA 
displayed lower overall A  levels (p = 4.5  ! 10 –2 ). There 
was a tendency toward lower levels of A  1–40 and A  1–42 
than in NDC, which missed the level of significance. The 
A  ratios as well as tau and p-tau levels were unaltered. 
 Neurochemical Phenotype of PPA versus AD. In com-
parison to AD, PPA displayed a tendency toward lower 
levels of A  1–38 , but this missed the level of significance. 
A  1–40 did not differ significantly, but A  1–42 was de-
creased in AD (p = 2.0  ! 10 –4 ). Consequently, the ratios 
of A  1–42 /A  1–40 (p = 5.9  ! 10 –5 ) and A  1–42 /A  1–38 (p = 
1.0  ! 10 –6 ) were decreased in AD. In contrast, the ratio 
of A  1–38 /A  1–40 was lowered in PPA (p = 4.5  ! 10 –2 ). 
CSF p-tau (p = 6.2  ! 10 –6 ), but not total tau, was signifi-
cantly elevated in AD.
 Neurochemical Phenotype of FTD versus PPA. FTD pa-
tients showed lower levels of A  1–38 (p = 1.6  ! 10 –2 ) than 
PPA patients, whereas A  1–42 and A  1–40 were unaltered 
between these 2 diagnostic groups. The A  ratios re-
mained virtually unchanged too. CSF total tau (p = 4.0  ! 
10 –2 ) and p-tau (p = 1.8  ! 10 –2 ) were elevated in PPA.
 Correlations 
 Throughout all investigated patient groups, the differ-
ent A  peptides were strongly correlated with each other, 
except for NDC and FTD, where a correlation of A  1–42 
to A  1–40 and A  1–38 , respectively, was lacking. Tau and 
p-tau were negatively correlated with A  1–42 . We found 
higher tau levels in younger AD patients, but levels of p-
tau and tau increased with age in NDC. Otherwise, none 
of the markers investigated, alone or in combination, 
were correlated with sex, age or severity of dementia in 
any of the groups investigated. All reported correlations 
reached the level of significance (p  ! 0.05).
 Discussion 
 In order to investigate disease-specific biomarker pat-
terns in FTLD subgroups, we evaluated CSF A  peptides 
1–40, 1–38 and 1–42 as well as total tau and p-tau 181 in 
patients with FTD and PPA in comparison with AD pa-
tients and NDC.
 The NDC group consisted of two subgroups, one with 
PND, the other DCC, which did not differ in any of the 
parameters investigated. The results of the AD group as 
compared to the NDC confirm our own previous results 
 [8, 16] and those from studies of others  [17] . The overlap-
ping CSF tau and A  1–42 levels between AD and the oth-
er dementia groups indicate a limited differential diag-
nostic value of these biomarkers.
 A  Peptide Patterns in FTD 
 FTD patients presented with low levels of A  1–38 as 
compared to NDC. Using electrochemiluminescence as 
an independent method, these results confirm our find-
ings from the A  -SDS-PAGE/immunoblot  [7, 8] . Al-
though less pronounced, CSF A  1–40 was reduced in FTD 
as measured by electrochemiluminescence. In previous 
studies, the A  -SDS-PAGE/immunoblot revealed no sig-
nificant change in A  1–40 , which may be due to method-
ological differences  [9] . Conflicting results of A  1–40 in 
FTD also arise from other studies. A recent study found 
a significant decrease in A  1–40 in FTLD compared with 
AD and control subjects  [5] . Another study reported a 
linear correlation between CSF A  1–40 levels and the de-
gree of frontal atrophy as measured by MRI in FTD, sug-
gesting higher CSF A  1–40 levels in FTD patients with 
more pronounced frontal atrophy  [6] . However, the re-
sults of the latter study are limited by the lack of a control 
group, which hampers a direct comparison to our results 
and those of others. The moderate decrease in A  1–42 in 
FTD as compared to NDC in the present study confirms 
our previous findings by A  -SDS-PAGE/immunoblot  [7, 
8] , as well as results from ELISA-based investigations of 
others  [3, 17] .
 In comparison to AD, FTD displayed lower levels of 
A  1–38 and A  1–40 accompanied by a less pronounced de-
crease in A  1–42 . Accordingly, FTD could be differenti-
ated from AD by either a decreased ratio of A  1–38 /A  1–40 
or increased ratios of A  1–42 /A  1–40 and A  1–42 /A  1–38 , 
respectively. These results match those of our previous 
reports  [7–9] and the study by Pijnenburg et al.  [5] . They 
underline the diagnostic usefulness not only of the ratios 
of A  1–42 /A  1–40 and A  1–42 /A  1–38 , but also of the ratio 
of A  1–38 /A  1–40 in differentiating FTD from AD. Within 
these ratios, decreased CSF A  1–38 may be considered as 
the most specific parameter of FTD as moderately dimin-
ished concentrations of A  1–42 and A  1–40 could also be 
found in other dementias such as dementia with Lewy 
bodies  [18] and vascular dementia  [19] .
 Bibl  /Mollenhauer  /Lewczuk  /Esselmann  /
Wolf  /Otto  /Kornhuber  /Rüther  /Wiltfang  
Dement Geriatr Cogn Disord 2011;31:37–4442
 Tau and p-Tau Proteins in FTD 
 The results of unchanged CSF tau levels and mildly 
decreased p-tau levels in FTD as compared to controls are 
in line with previous studies by others  [17, 20] . The de-
crease in CSF p-tau in FTD as compared to controls may 
be explained by disturbances of tau phosphorylation reg-
ulatory mechanisms in FTD  [20] . Another explanation 
may be an underlying AD pathology in NDC, especially 
in the subgroup of DCC, as depression in the elderly may 
also be a prodromal state of AD. Compared to AD, FTD 
presented with both lower tau and lower p-tau levels in 
CSF. These findings are in accordance with the literature 
 [2, 3, 17, 20] .
 A  Peptide Patterns in PPA  
 None of the investigated A  peptides differed signifi-
cantly between PPA and NDC. The major differences be-
tween PPA and AD were the decreased CSF levels of
A  1–42 and, subsequently, the ratios of A  1–42 /A  1–40 and 
A  1–42 /A  1–38 in the latter. Due to stable CSF A  1–40 lev-
els in both groups, paralleled by a tendency toward high-
er and lower CSF A  1–38 levels in AD and PPA, respec-
tively, the ratio of A  1–38 /A  1–40 differed between the two 
diagnostic groups.
 When comparing the CSF A  peptide patterns of 
PPA and FTD, the only difference was lower levels of 
A  1–38 in the latter. This may somehow indicate a spec-
ificity of decreased CSF A  1–38 levels in FTD as com-
pared to other subgroups of the FTLD spectrum. How-
ever, due to the lack of a confirmative neuropathological 
diagnosis, the pathophysiological implications of this 
finding remain to be elucidated in further investiga-
tions. Nevertheless, there is evidence of three distinct 
presenilin 1 mutations causing a clinical phenotype of 
FTD  [21, 22] , indicating a role of A  peptide metabolism 
in the neurodegenerative process of FTD. Interestingly, 
presenilin mutations are also the most common cause 
of familial AD.
 To the best of our knowledge, this is the first study on 
the three major CSF A  peptides 1–40, 1–38 and 1–42 in 
the distinct group of PPA. A multiple case evaluation of 
patients with PPA (n = 3) reported CSF A  1–42 to be in the 
normal range  [23] . A subgroup evaluation of a study on 
the CSF biomarkers tau, p-tau and A  1–42 in 34 patients 
with FTLD in comparison to AD and control subjects 
found PPA to have the smallest overlap with AD-typical 
CSF biomarker patterns  [24] . Despite large methodologi-
cal differences between those studies, the results indicate 
A  1–42 to be in the normal range in most patients with 
PPA, which is in line with our results. Although it missed 
the level of significance, we noted a weak tendency to-
ward lower CSF A  1–42 levels in PPA than in NDC. This 
may be caused by overlapping AD pathology in PPA and 
may become more evident in a larger cohort of PPA pa-
tients. However, we cannot completely exclude the pos-
sibility that AD and PPA diagnoses have been mixed up. 
We did not find any previous report on CSF A  1–38 and 
A  1–40 in PPA.
 Tau and p-Tau Proteins in PPA 
 Neither tau nor p-tau was significantly altered be-
tween PPA and NDC. However, a previous multiple case 
report found slightly elevated tau levels in 3 cases of PPA 
 [23] . In another study on biomarkers in FTLD, a sub-
group analysis revealed PPA to show the smallest overlap 
with AD-typical CSF biomarker patterns, indicating 
rather normal values for tau in the group of PPA  [24] . 
Otherwise, tau was not able to differentiate PPA from AD 
in our study. Thus, CSF tau may somehow be a variable 
parameter in PPA, probably correlating more closely with 
the actual degree of neurodegeneration at the time of 
lumbar puncture than with the underlying disease entity. 
Interestingly, tau was significantly lower in FTD than in 
PPA, indicating a higher dynamic of neurodegeneration 
in the latter.
 p-tau levels were also elevated in PPA, when compared 
to FTD, which may support the abovementioned hypoth-
esis about possible dysfunction of phosphorylation regu-
latory mechanisms in FTD  [20] . In comparison to AD, 
p-tau levels were significantly lower in PPA, underlining 
the differential diagnostic value of this parameter for AD 
differential diagnosis among dementias of other kind. 
Thus, hyperphosphorylation of tau remains a specific 
pathogenic core feature of AD in contrast to other de-
mentias. Moreover, it seems that, due to a thorough clin-
ical diagnostic workup, AD and PPA diagnoses have been 
mixed up only to a limited extend.
 Limitations of the Study 
 The reliance on clinical diagnosis limits the validity of 
our results because of potential misclassification. Anoth-
er point of concern is that the methods used for measure-
ment varied between A  1–38 and A  1–40 or A  1–42 . How-
ever, an ELISA for A  1–38 was not yet available at the time 
of measurement. Moreover, the analyses of p-tau, A  1–38 
and A  1–40 were made with frozen samples, whereas
A  1–42 and total tau ELISA were conducted with unfro-
zen CSF samples.
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 Conclusions 
 This is the first detailed report on biomarker patterns 
in PPA including the three most prominent A  peptides 
in CSF (1–40, 1–38 and 1–42) in addition to the widely 
accepted AD CSF biomarkers tau and p-tau. The evalua-
tion of these markers in PPA as compared to AD, FTD 
and NDC confirmed high p-tau levels and low levels of 
A  1–42 /A  1–40 and A  1–42 /A  1–38 as specific features of 
AD as compared to other dementias. Moreover, the find-
ing of low CSF A  1–38 levels in FTD could be confirmed. 
Interestingly, PPA did not show this feature. In addition, 
PPA patients showed higher levels of CSF tau and p-tau 
than did FTD patients. Thus, our results show distinct 
CSF biomarker patterns for FTD and PPA. Further stud-
ies on larger patient groups will have to clarify the diag-
nostic value of this finding. Otherwise, a distinct clinical 
presentation may be related to different kinds of neuro-
pathology. Thus, the investigation of more homogeneous 
patient groups with neuropathologically confirmative di-
agnoses may display CSF biomarker changes even more 
precisely. This approach may also elucidate the patho-
physiological implications of our results. We are con-
vinced that these aspects deserve further investigation in 
appropriately designed studies.
 Acknowledgments 
 This study was supported by the following grants: cNEUPRO 
(EU contract No. LSHM-CT-2007-037950) and neuroTAS (EU 
contract No. LSHB-CT-2006-037953). The authors would like to 




 1 Neary D, Snowden JS, Gustafson L, Passant 
U, Stuss D, Black S, Freedman M, Kertesz A, 
Robert PH, Albert M, Boone K, Miller BL, 
Cummings J, Benson DF: Frontotemporal 
lobar degeneration: a consensus on clini-
cal diagnostic criteria. Neurology 1998; 51: 
 1546–1554. 
 2 Sjögren M, Minthon L, Davidson P, Gra-
nerus AK, Clarberg A, Vanderstichele H, 
Vanmechelen E, Wallin A, Blennow K: CSF 
levels of tau,   -amyloid 1–42 and GAP-43 in 
frontotemporal dementia, other types of de-
mentia and normal aging. J Neural Transm 
2000; 107: 563–579. 
 3 Riemenschneider M, Wagenpfeil S, Diehl J, 
Lautenschlager N, Theml T, Heldmann B, 
Drzezga A, Jahn T, Förstl H, Kurz A: Tau and 
A  42 protein in CSF of patients with fronto-
temporal degeneration. Neurology 2002; 58: 
 1622–1628. 
 4 Galasko D, Marder K: Picking away at fron-
totemporal dementia. Neurology 2000; 58: 
 1585–1586. 
 5 Pijnenburg YA, Schoonenboom SN, Mehta 
PD, Mehta SP, Mulder C, Veerhuis R, Blan-
kenstein MA, Scheltens P: Decreased cere-
brospinal f luid amyloid beta 1–40 levels in 
frontotemporal lobar degeneration. J Neurol 
Neurosurg Psychiatry 2007; 78: 735–737. 
 6 Andersen C, Jensen M, Lannfelt L, Lindau 
M, Wahlund LO: Amyloid A  40 CSF concen-
trations correlate to frontal lobe atrophy
in frontotemporal dementia. Neuroreport 
2000; 11: 287–290. 
 7 Bibl M, Mollenhauer B, Wolf S, Esselmann 
H, Lewczuk P, Kornhuber J, Wiltfang J: Re-
duced CSF carboxyterminally truncated A  
peptides in frontotemporal lobe degenera-
tions. J Neural Transm 2007; 114: 621–628. 
 8 Bibl M, Mollenhauer B, Lewczuk P, Essel-
mann H, Wolf S, Trenkwalder C, Otto M, 
Stiens G, Rüther E, Kornhuber J, Wiltfang J: 
Validation of amyloid-  peptides in CSF 
 diagnosis of neurodegenerative dementias. 
Mol Psychiatry 2007; 12: 671–680. 
 9 Bibl M, Lewczuk P, Esselmann H, Mollen-
hauer B, Klafki HW, Welge V, Wolf S,
Trenkwalder C, Otto M, Kornhuber J, Wilt-
fang J: CSF amyloid-  1–38 and 1–42 in FTD 
and AD: biomarker performance critically 
depends on the detergent accessible fraction. 
Proteomics Clin Appl 2008; 2: 1548–1556. 
 10 Steinacker P, Hendrich C, Sperfeld AD, Jesse 
S, Lehnert S, Pabst A, von Arnim CA, Mot-
taghy FM, Uttner I, Tumani H, Ludolph A, 
Otto M: Concentrations of   -amyloid pre-
cursor protein processing products in cere-
brospinal f luid of patients with amyotrophic 
lateral sclerosis and frontotemporal lobar 
degeneration. J Neural Transm 2009; 116: 
 1169–1178. 
 11 Steinacker P, Hendrich C, Sperfeld AD, Jesse 
S, von Arnim CA, Lehnert S, Pabst A, Uttner 
I, Tumani H, Lee VM, Trojanowski JQ, 
Kretzschmar HA, Ludolph A, Neumann M, 
Otto M: TDP-43 in cerebrospinal f luid of pa-
tients with frontotemporal lobar degenera-
tion and amyotrophic lateral sclerosis. Arch 
Neurol 2008; 65: 1481–1487. 
 12 World Medical Organisation: Declaration of 
Helsinki. BMJ 1996; 313: 1448–1449. 
 13 McKhann G, Drachman D, Folstein M, 
Katzmann R, Price D, Stadlan EM: Clinical 
diagnosis of Alzheimer’s disease: report of 
the NINCDS-ADRDA Work Group under 
the auspices of Department of Health and 
Human Services Task Force on Alzheimer’s 
Disease. Neurology 1984; 34: 939–944. 
 14 Vanmechelen E, Vanderstichele H, Davids-
son P, van Kerschaver E, van der Perre B, 
Sjögren M, Andreasen N, Blennow K: Quan-
tification of tau phosphorylated at threonine 
181 in human cerebrospinal f luid: a sand-
wich ELISA with a synthetic phosphopeptide 
for standardization. Neurosci Lett 2000; 285: 
 49–52. 
 15 Hulstaert F, Blennow K, Ivanoiu A, 
Schoonderwald HC, Riemenschneider M, de 
Deyn PP, Bancher C, Cras P, Wiltfang J, 
Mehta PD, Iqbal K, Pottel H, Vanmechelen
E, Vanderstichele H: Improved discrimina-
tion of AD-patients using   -amyloid 1–42 and 
tau levels in CSF. Neurology 1999; 52: 1555–
1562. 
 16 Wiltfang J, Esselmann H, Bibl M, Smirnov A, 
Otto M, Paul S, Schmid B, Klafki HW, Maler 
M, Dyrks T, Bienert M, Beyermann M, Rüt-
her E, Kornhuber J: Highly conserved and 
disease-specific patterns of carboxytermi-
nally truncated A  peptides 1–37/38/39 in 
addition to 1–40/42 in Alzheimer’s disease 
and patients with chronic neuroinflamma-
tion. J Neurochem 2002; 81: 481–496. 
 17 Blennow K: Cerebrospinal f luid protein bio-
markers for Alzheimer’s disease. NeuroRx 
2004; 1: 213–225. 
 Bibl  /Mollenhauer  /Lewczuk  /Esselmann  /
Wolf  /Otto  /Kornhuber  /Rüther  /Wiltfang  
Dement Geriatr Cogn Disord 2011;31:37–4444
 18 Bibl M, Mollenhauer B, Esselmann H, Lew-
czuk P, Trenkwalder C, Rüther E, Kornhuber 
J, Otto M, Wiltfang J: CSF diagnosis of
Alzheimer’s disease and dementia with Lewy 
bodies. J Neural Transm 2006; 114: 621–628. 
 19 Bibl M, Mollenhauer B, Esselmann H,
Schneider M, Lewczuk P, Welge V, Gross M, 
Falkai P, Kornhuber J, Wiltfang J: Cerebro-
spinal f luid neurochemical phenotypes in 
vascular dementias: original data and mini-
review. Dement Geriatr Cogn Disord 2008; 
 25: 256–265. 
 20 Sjögren M, Davidsson P, Tullberg M, Mint-
hon L, Wallin A, Wikkelso C, Granérus AK, 
Vanderstichele H, Vanmechelen E, Blennow 
K: Both total and phosphorylated tau are in-
creased in Alzheimer’s disease. J Neurol 
Neurosurg Psychiatry 2001; 70: 624–630. 
 21 Dermaut B, Kumar-Singh S, Engelborghs S, 
Theuns J, Rademakers R, Saerens J, Pickut 
BA, Peeters K, van den Broeck M, Vennekens 
K, Claes S, Cruts M, Cras P, Martin JJ, van 
Broeckhoven C, de Deyn PP: A novel prese-
nilin 1 mutation associated with Pick’s dis-
ease but not   -amyloid plaques. Ann Neurol 
2004; 55: 617–626. 
 22 Zekanowski C, Golan MP, Krzysko KA, Lip-
czynska-Lojkowska W, Filipek S, Kowalska 
A, Rossa G, Peplonska B, Styczynska M, 
Maruszak A, Religa D, Wender M, Kulczycki 
J, Barcikowska M, Kuznicki J: Two novel pre-
senilin 1 gene mutations connected with 
frontotemporal dementia-like clinical phe-
notype: genetic and bioinformatic assess-
ment. Exp Neurol 2006; 200: 82–88. 
 23 Maeck L, Meller J, Otto M, Stiens G, Wilt-
fang J, Stoppe G: A  peptide 1–42, tau pro-
tein and S-100B protein level in cerebrospi-
nal f luid of three patients with primary pro-
gressive aphasia. Neurosci Lett 2002; 333: 
 33–36. 
 24 Kapaki E, Paraskevas GP, Papageorgiou SG, 
Bonakis A, Kalfakis N, Zalonis I, Vassilo-
poulos D: Diagnostic value of CSF biomark-
er profile in frontotemporal lobar degenera-
tion. Alzheimer Dis Assoc Disord 2008; 22: 
 47–53. 
 
